Xencor

XNCR NASDAQ
44.59
-1.00
-2.19%
盘后: 44.59 0 0.00% 18:41 07/19 EDT
开盘
45.42
昨收
45.59
最高
45.86
最低
44.08
成交量
36.00万
成交均量(3M)
48.52万
52周最高
48.38
52周最低
27.75
换手率
0.64%
市值
25.13亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Xencor XNCR股票价格,Xencor股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
展开 >

最近浏览

名称
价格
涨跌幅